Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment
Boris Blechacz, Gregory J. Gores – 20 June 2008
Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004
Cristina Bosetti, Fabio Levi, Paolo Boffetta, Franca Lucchini, Eva Negri, Carlo La Vecchia – 20 June 2008 – Upward trends in mortality from hepatocellular carcinoma (HCC) were recently reported in the United States and Japan. Comprehensive analyses of most recent data for European countries are not available. Age‐standardized (world standard) HCC rates per 100,000 (at all ages, at age 20‐44, and age 45‐59 years) were computed for 23 European countries over the period 1980‐2004 using data from the World Health Organization.
Granulocyte‐colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: A randomized trial
Laurent Spahr, Jean‐François Lambert, Laura Rubbia‐Brandt, Yves Chalandon, Jean‐Louis Frossard, Emiliano Giostra, Antoine Hadengue – 20 June 2008 – Liver failure is the major cause of death in alcoholic steatohepatitis (ASH). In experimental hepatitis, granulocyte‐colony stimulating factor (G‐CSF) mobilizes hematopoietic stem cells, induces liver regeneration, and improves survival. We studied the short‐term effects of G‐CSF on CD34+ stem cell mobilization, liver cell proliferation, and liver function in patients with ASH.
Antiviral effects of silymarin against hepatitis C: The jury is still out
Stephen J. Polyak, Chihiro Morishima, Roy Hawke – 20 June 2008
Host neutralizing responses and pathogenesis of hepatitis C virus infection
Mirjam B. Zeisel, François‐Loïc Cosset, Thomas F. Baumert – 20 June 2008
The need for better clinical trials
Patrick S. Kamath – 20 June 2008
Does retinol‐binding protein 4 cause or reflect fatty liver disease?
Matthias Blüher, Anke Tönjes, Michael Stumvoll – 20 June 2008
Closing the door on hepatitis B
C.‐Thomas Bock, Joseph Torresi – 20 June 2008
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound
Nadia Warner, Stephen Locarnini – 20 June 2008 – The hepatitis B virus (HBV) mutation that encodes rtA181T is selected in the viral polymerase during antiviral drug therapy and can also encode a stop codon in the overlapping surface gene at amino acid 172 (sW172*) resulting in truncation of the last 55 amino acids of the C‐terminal hydrophobic region of the surface proteins. This mutation is usually detected as a mixed population with wild‐type HBV.
Retinol‐binding protein 4: A new marker of virus‐induced steatosis in patients infected with hepatitis c virus genotype 1
Salvatore Petta, Calogero Cammà, Vito Di Marco, Nicola Alessi, Francesco Barbaria, Daniela Cabibi, Rosalia Caldarella, Stefania Ciminnisi, Anna Licata, Maria Fatima Massenti, Alessandra Mazzola, Giuseppe Tarantino, Giulio Marchesini, Antonio Craxì – 20 June 2008 – Retinol‐binding protein 4 (RBP4) is an adipocytokine associated with insulin resistance (IR). We tested serum levels of RBP4 to assess its link with steatosis in patients with genotype 1 chronic hepatitis C (CHC) or nonalcoholic fatty liver disease (NAFLD).